Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
$24.97
-$1.37(-3.96%)
At close: 4:00 PM EST
$24.97
-$1.37(-3.96%)
Day’s Range― - ―
52-Week Range$16.10 - $35.57
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.29M
Market Cap
$3.18B
Enterprise Value$2.94B
Total Cash (Recent Filing)$479.17M
Total Debt (Recent Filing)$475.37M
Price to Earnings (P/E)84.7
Beta0.95
Next Earnings
Mar 04, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding126,525,215
10 Day Avg. Volume2,531,202
30 Day Avg. Volume2,294,189
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)17.30
Price to Sales (P/S)5.06
P/FCF Ratio-44.79
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda31.47
Forecast
1Y Price Target
$42.23Price Target Upside69.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.26
Revenue Forecast (FY)$1.00B
Bulls Say, Bears Say
Bulls Say
Market LeadershipSyfovre remains the market leader in GA with 60% share, and Syfovre has maintained its share in new patient starts (52%).
Regulatory ApprovalsThe European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of Aspaveli for the treatment of rare kidney diseases, paving the way for an approval decision by the European Commission.
Revenue OpportunitiesRecent regulatory progress and approval in C3G and IC-MPGN open up a significant revenue opportunity for Apellis that should start meaningfully contributing to top-line growth.
Bears Say
Funding IssuesSyfovre's sluggish growth is driven by a persistent funding gap at co-pay assistance foundations, negatively impacting revenue.
Market FragmentationFragmented market and potential payor access issues could limit Empaveli uptake.
Revenue Growth ChallengesSyfovre sales growth is muted as headwinds persist, impacting revenue growth.
Apellis Pharmaceuticals News
APLS FAQ
What was Apellis Pharmaceuticals’s price range in the past 12 months?
Apellis Pharmaceuticals lowest stock price was $16.10 and its highest was $35.57 in the past 12 months.
What is Apellis Pharmaceuticals’s market cap?
Apellis Pharmaceuticals’s market cap is $3.18B.
When is Apellis Pharmaceuticals’s upcoming earnings report date?
Apellis Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 66 days.
How were Apellis Pharmaceuticals’s earnings last quarter?
Apellis Pharmaceuticals released its earnings results on Oct 30, 2025. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.579 by $0.091.
Is Apellis Pharmaceuticals overvalued?
According to Wall Street analysts Apellis Pharmaceuticals’s price is currently Undervalued.
Does Apellis Pharmaceuticals pay dividends?
Apellis Pharmaceuticals does not currently pay dividends.
What is Apellis Pharmaceuticals’s EPS estimate?
Apellis Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Apellis Pharmaceuticals have?
Apellis Pharmaceuticals has 126,525,215 shares outstanding.
What happened to Apellis Pharmaceuticals’s price movement after its last earnings report?
Apellis Pharmaceuticals reported an EPS of $1.67 in its last earnings report, beating expectations of $1.579. Following the earnings report the stock price went down -31.015%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals?
Currently, no hedge funds are holding shares in APLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apellis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.23 (69.12% Upside)
$42.23 (69.12% Upside)
Blogger Sentiment
Neutral
APLS Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.23%
12-Months-Change
Fundamentals
Return on Equity
14.10%
Trailing 12-Months
Asset Growth
17.39%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
APLS Company Deck
APLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected significant progress with the FDA approval of EMPAVELI and strong market leadership of SYFOVRE. However, challenges in SYFOVRE revenue due to free drug programs and operational challenges in patient access were notable concerns.View all APLS earnings summariesAPLS Stock 12 Month Forecast
Average Price Target
$42.23
▲(69.12% Upside)
Technical Analysis
Zai Lab
―
Crinetics Pharmaceuticals
―
―
Mirum Pharmaceuticals
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.17% Insiders
18.12% Mutual Funds
41.87% Other Institutional Investors
22.07% Public Companies and Individual Investors